Michelle Gompelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michelle Gompelman has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Chantal P. Bleeker-Rovers
Department of Internal Medicine, Division of Infectious Diseases, Radboud university medical center, Nijmegen, The Netherlands
5 shared publicationsGeert J.A. Wanten
Intestinal Failure Unit, Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands
4 shared publications- Geert J. A. Wanten
Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications Heiman F.L. Wertheim
Department of Medical Microbiology and Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publicationsChantal P Rovers
Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center , Nijmegen
2 shared publications- Chantal P. Bleeker-Rovers
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2 shared publications
Latest Publications
- 5 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 314
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!—authors’ response
We read with interest the comments by Deleenheer et al.1 on our study ‘Oral antimicrobial agents in patients with short bowel syndrome: worth a try!’ and thank the authors for the constructive reflection on our findings.2 The authors suggest a more cautious interpretation of our findings and recommend therapeutic drug monitoring (TDM) for all drugs used in our study. First, it is important to emphasize that our study was exploratory in nature—a first attempt to investigate the pharmacokinetics of oral antimicrobials in this population. This work is an initial step in building the knowledge necessary for the use of oral therapy in clinical practice in this group. We acknowledge that more research is needed before oral antimicrobial agents can be routinely used in all short bowel syndrome (SBS) patients. Deleenheer et al. raise fair points regarding the variable bioavailability and remaining small bowel length of our included patients, which are aspects we have certainly considered. Given the wide clinical heterogeneity of SBS patients, we acknowledge that the current use of oral antimicrobials in SBS patients requires TDM to warrant adequate drug exposure.
- 5 November 2024
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 80 (1) , 314
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!—authors’ response
We read with interest the comments by Deleenheer et al.1 on our study ‘Oral antimicrobial agents in patients with short bowel syndrome: worth a try!’ and thank the authors for the constructive reflection on our findings.2 The authors suggest a more cautious interpretation of our findings and recommend therapeutic drug monitoring (TDM) for all drugs used in our study. First, it is important to emphasize that our study was exploratory in nature—a first attempt to investigate the pharmacokinetics of oral antimicrobials in this population. This work is an initial step in building the knowledge necessary for the use of oral therapy in clinical practice in this group. We acknowledge that more research is needed before oral antimicrobial agents can be routinely used in all short bowel syndrome (SBS) patients. Deleenheer et al. raise fair points regarding the variable bioavailability and remaining small bowel length of our included patients, which are aspects we have certainly considered. Given the wide clinical heterogeneity of SBS patients, we acknowledge that the current use of oral antimicrobials in SBS patients requires TDM to warrant adequate drug exposure.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1285-1288
Genomic Characterization of Methicillin-Susceptible Staphylococcus aureus Carriage in Patients on Home Parenteral Nutrition and Their Caregivers
In this prospective study, patients on home parenteral nutrition were twice as likely to be colonized with Staphylococcus aureus if their caregivers were carriers. Among S. aureus-positive patients and their caregivers, molecular analysis showed 68% genetically related strains. Despite decolonization, genetically related strains reappeared in 70% of patients.
- 27 November 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1285-1288
Open AccessGenomic Characterization of Methicillin-Susceptible Staphylococcus aureus Carriage in Patients on Home Parenteral Nutrition and Their Caregivers
In this prospective study, patients on home parenteral nutrition were twice as likely to be colonized with Staphylococcus aureus if their caregivers were carriers. Among S. aureus-positive patients and their caregivers, molecular analysis showed 68% genetically related strains. Despite decolonization, genetically related strains reappeared in 70% of patients.
- 4 October 2023
- Published by Springer Nature
- p. 849-856
Prevention, Diagnosis and Management of Catheter-Related Blood Stream Infections
- 4 October 2023
- Published by Springer Nature
- p. 849-856
Prevention, Diagnosis and Management of Catheter-Related Blood Stream Infections
- Open Access
- 30 June 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (8) , 2008-2014
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!
Background: The use of oral antimicrobial agents in patients with short bowel syndrome (SBS) is challenging due to the changes in gastrointestinal anatomy that may result in diminished absorption and altered drug bioavailability. Prospective studies evaluating bioavailability of antimicrobial agents after oral administration in SBS patients are lacking. Objectives: To determine the bioavailability of orally administered antimicrobial agents commonly used for treatment in SBS patients to guide clinical decision making when faced with infections. Methods: We performed an explorative, clinical study investigating the pharmacokinetics (PK) of clindamycin, ciprofloxacin, flucloxacillin and fluconazole in SBS patients with intestinal failure. Participants received a combination of two antimicrobial agents simultaneously. To determine the oral bioavailability, participants received a single oral and IV dose of both agents on two occasions, after which they underwent intensive PK sampling on six predefined time points up to 12 hours after administration. Primary outcome was the oral bioavailability of these antimicrobial agents. Secondary outcomes were intravenous PK characteristics following non-compartmental analysis. Results: Eighteen SBS patients were included: the mean (SD) age was 59 (17) years and 61% of participants were female. The median observed (IQR) bioavailability of ciprofloxacin, clindamycin, flucloxacillin and fluconazole were 36% (24–50), 93% (56–106), 50% (32–76) and 98% (61–107), respectively. Conclusion: The bioavailability of selected antimicrobial agents in certain patients with SBS appeared to be better than expected, providing a feasible treatment option. Due to the large observed differences between patients, therapeutic drug monitoring should be part of the treatment to safeguard adequate exposure in all patients. Trial registration: Registered in the Dutch Trial Register (NL7796) and EudraCT number 2019-002587-28
- 30 June 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (8) , 2008-2014
Open AccessOral antimicrobial agents in patients with short bowel syndrome: worth a try!
Background: The use of oral antimicrobial agents in patients with short bowel syndrome (SBS) is challenging due to the changes in gastrointestinal anatomy that may result in diminished absorption and altered drug bioavailability. Prospective studies evaluating bioavailability of antimicrobial agents after oral administration in SBS patients are lacking. Objectives: To determine the bioavailability of orally administered antimicrobial agents commonly used for treatment in SBS patients to guide clinical decision making when faced with infections. Methods: We performed an explorative, clinical study investigating the pharmacokinetics (PK) of clindamycin, ciprofloxacin, flucloxacillin and fluconazole in SBS patients with intestinal failure. Participants received a combination of two antimicrobial agents simultaneously. To determine the oral bioavailability, participants received a single oral and IV dose of both agents on two occasions, after which they underwent intensive PK sampling on six predefined time points up to 12 hours after administration. Primary outcome was the oral bioavailability of these antimicrobial agents. Secondary outcomes were intravenous PK characteristics following non-compartmental analysis. Results: Eighteen SBS patients were included: the mean (SD) age was 59 (17) years and 61% of participants were female. The median observed (IQR) bioavailability of ciprofloxacin, clindamycin, flucloxacillin and fluconazole were 36% (24–50), 93% (56–106), 50% (32–76) and 98% (61–107), respectively. Conclusion: The bioavailability of selected antimicrobial agents in certain patients with SBS appeared to be better than expected, providing a feasible treatment option. Due to the large observed differences between patients, therapeutic drug monitoring should be part of the treatment to safeguard adequate exposure in all patients. Trial registration: Registered in the Dutch Trial Register (NL7796) and EudraCT number 2019-002587-28
- Open Access
- 17 March 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (5) , 706-716
Randomized clinical trial: Long-term Staphylococcus aureus decolonization in patients on home parenteral nutrition
- 17 March 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (5) , 706-716
Open AccessRandomized clinical trial: Long-term Staphylococcus aureus decolonization in patients on home parenteral nutrition
- Open Access
- 8 June 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 50, 155-161
Catheter-related bloodstream infection management in patients receiving home parenteral nutrition: An observational cohort study
- 8 June 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 50, 155-161
Open AccessCatheter-related bloodstream infection management in patients receiving home parenteral nutrition: An observational cohort study
- Open Access
- 20 December 2021
- Published by Springer Nature in Infection
- Vol. 50 (2) , 491-498
Individualizing the use of [18F]FDG-PET/CT in patients with complicated Staphylococcus aureus bacteremia: experiences from a tertiary care center
Purpose: [18F]FDG-PET/CT scanning can help detect metastatic infectious foci and reduce mortality in patients with Staphylococcus aureus bacteremia (SAB), but it is unknown if patients with SAB and an indication for prolonged treatment because of possible endovascular, orthopaedic implant, or other metastatic infection still need [18F]FDG-PET/CT. Methods: In a retrospective single-center cohort study, we included all consecutive adult patients with SAB between 2013 and 2020 if an [18F]FDG-PET/CT scan was performed and antibiotic treatment was planned for ≥ 6 weeks prior to [18F]FDG-PET/CT. We aimed to identify patients for whom treatment was adjusted due to the results of [18F]FDG-PET/CT, and assessed concordance of [18F]FDG-PET/CT and clinical diagnosis for infected prosthetic material. Results: Among 132 patients included, the original treatment plan was changed after [18F]FDG-PET/CT in 22 patients (16.7%), in the majority (n = 20) due to diagnosing or rejecting endovascular (graft) infection. Antibiotic treatment modifications were shortening in 2, iv-oral switch in 3, extension in 13, and addition of rifampicin in 4 patients. Ninety additional metastatic foci based on [18F]FDG-PET/CT results were found in 69/132 patients (52.3%). [18F]FDG-PET/CT suggested vascular graft infection in 7/14 patients who lacked clinical signs of infection, but showed no infection of prosthetic joints or osteosynthesis material in eight patients who lacked clinical signs of such an infection. Conclusion: [18F]FDG-PET/CT can help refine treatment for SAB in patients with clinically suspected endovascular infection or vascular grafts, even if 6 weeks treatment is already indicated, but can be safely omitted in other patients who are clinically stable.
- 20 December 2021
- Published by Springer Nature in Infection
- Vol. 50 (2) , 491-498
Open AccessIndividualizing the use of [18F]FDG-PET/CT in patients with complicated Staphylococcus aureus bacteremia: experiences from a tertiary care center
Purpose: [18F]FDG-PET/CT scanning can help detect metastatic infectious foci and reduce mortality in patients with Staphylococcus aureus bacteremia (SAB), but it is unknown if patients with SAB and an indication for prolonged treatment because of possible endovascular, orthopaedic implant, or other metastatic infection still need [18F]FDG-PET/CT. Methods: In a retrospective single-center cohort study, we included all consecutive adult patients with SAB between 2013 and 2020 if an [18F]FDG-PET/CT scan was performed and antibiotic treatment was planned for ≥ 6 weeks prior to [18F]FDG-PET/CT. We aimed to identify patients for whom treatment was adjusted due to the results of [18F]FDG-PET/CT, and assessed concordance of [18F]FDG-PET/CT and clinical diagnosis for infected prosthetic material. Results: Among 132 patients included, the original treatment plan was changed after [18F]FDG-PET/CT in 22 patients (16.7%), in the majority (n = 20) due to diagnosing or rejecting endovascular (graft) infection. Antibiotic treatment modifications were shortening in 2, iv-oral switch in 3, extension in 13, and addition of rifampicin in 4 patients. Ninety additional metastatic foci based on [18F]FDG-PET/CT results were found in 69/132 patients (52.3%). [18F]FDG-PET/CT suggested vascular graft infection in 7/14 patients who lacked clinical signs of infection, but showed no infection of prosthetic joints or osteosynthesis material in eight patients who lacked clinical signs of such an infection. Conclusion: [18F]FDG-PET/CT can help refine treatment for SAB in patients with clinically suspected endovascular infection or vascular grafts, even if 6 weeks treatment is already indicated, but can be safely omitted in other patients who are clinically stable.
- Open Access
- 1 December 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 144, 112296
The diagnostic value of [18F]FDG-PET/CT in detecting septic thrombosis in patients with central venous catheter-related Staphylococcus aureus bacteremia
- 1 December 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 144, 112296
Open AccessThe diagnostic value of [18F]FDG-PET/CT in detecting septic thrombosis in patients with central venous catheter-related Staphylococcus aureus bacteremia
- 7 September 2021
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 46 (6) , 821-823
Oral Antibiotics in Patients with Short Bowel Syndrome: Do or Don’t?
- 7 September 2021
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 46 (6) , 821-823
Oral Antibiotics in Patients with Short Bowel Syndrome: Do or Don’t?